Things For Investors To Watch In iBio Inc (AMEX: IBIO)

iBio Inc (AMEX:IBIO) does about 3.67M shares in volume on a normal day but saw 5616535 shares change hands in Monday’s trading. The company now has a market cap of 11.66M USD. Its current market price is $3.35, marking a decrease of -17.49% compared to the previous close of $4.06. The 52 week high reached by this stock is $49.00 whilst the lowest price level in 52 weeks is $1.02.

iBio Inc (IBIO) has a 20-day trading average at $1.50 and the current price is -93.16% off the 52-week high compared with 227.98% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.30 and its 200-day simple moving average is $5.29. If we look at the stock’s price movements over the week, volatility stands at 31.32%, which decreases to 10.99% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 76.18 to suggest the stock is overbought.

The consensus objective for the share price is $20.00, suggesting that the stock has a potential upside of 83.25% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 29, 2021 when JMP Securities initiated the stock to “Mkt Outperform” and issued a price target of $1.50. Alliance Global Partners initiated its price target at $2.55.

iBio Inc (IBIO) stock is up 207.34% over the week and 165.87% over the past month. Its price is 144.53% year-to-date and -92.52% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2023, with the company’s earnings per share (EPS) of $0.26 above consensus estimates by $0.67.

To reach the target analysts have set, the stock logically needs to grow 83.25 percent from here.

Outstanding shares total 3.48M with insiders holding 0.44% of the shares and institutional holders owning 7.22% of the company’s common stock. The company has a return on investment of -221.57% and return on equity of -148.27%. The beta has a value of -3.54. Price to book ratio is 1.18 and price to sales ratio is 233.16.